This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ flavoxate hydrochloride,(prescription) [Can cause cognitive issues]

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antineoplastic Activity: Floxuridine belongs to the class of medications known as antimetabolites. It works by interfering with the synthesis of DNA and RNA, which are essential for the growth and replication of cancer cells. By inhibiting nucleic acid synthesis, floxuridine prevents cancer cells from proliferating and induces their death.

  2. Treatment of Colorectal Cancer: Floxuridine is commonly used in the treatment of colorectal cancer, particularly when the cancer has spread to the liver (metastatic colorectal cancer). It may be administered directly into the hepatic artery (intra-arterial infusion) to target tumors in the liver.

  3. Administration Route: Floxuridine is typically administered as an intravenous infusion or through direct injection into the hepatic artery. In the case of hepatic artery infusion, floxuridine is delivered directly to the liver, allowing for higher concentrations of the drug to reach the tumor while minimizing systemic side effects.

  4. Adverse Effects: Common side effects of floxuridine may include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and mucositis (inflammation of the mucous membranes). Bone marrow suppression, resulting in decreased production of blood cells (myelosuppression), may also occur, leading to anemia, leukopenia, and thrombocytopenia.

  5. Liver Toxicity: Floxuridine can cause hepatotoxicity (liver damage), particularly when administered via hepatic artery infusion. Hepatic artery occlusion or liver dysfunction may occur as a result of the infusion procedure, necessitating close monitoring of liver function during treatment.

  6. Hand-Foot Syndrome: Floxuridine may cause a side effect known as hand-foot syndrome (palmar-plantar erythrodysesthesia), characterized by redness, swelling, and pain in the palms of the hands and soles of the feet. This condition can be dose-limiting and may require dose adjustments or discontinuation of treatment.

  7. Bone Marrow Suppression: Floxuridine can suppress bone marrow function, leading to a decreased production of white blood cells, red blood cells, and platelets. This can increase the risk of infections, anemia, and bleeding, necessitating regular monitoring of blood cell counts during treatment.

  8. Contraindications and Precautions: Floxuridine is contraindicated in individuals with known hypersensitivity to the drug or its components. It should be used with caution in patients with preexisting liver disease or impaired bone marrow function. Pregnancy and breastfeeding are generally contraindicated due to the potential risk of harm to the fetus or infant.

  9. Monitoring and Supportive Care: Patients receiving floxuridine therapy require close monitoring of liver function, blood cell counts, and renal function. Supportive care measures, such as antiemetic medications to manage nausea and vomiting, may be prescribed to improve tolerance to treatment.

  10. Combination Therapy: Floxuridine may be used in combination with other chemotherapy drugs or radiation therapy as part of a multidisciplinary approach to cancer treatment. The choice of treatment regimen depends on factors such as the type and stage of cancer, as well as the patient's overall health and treatment goals.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations

βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of flavoxate hydrochloride,(prescription) [Can cause cognitive issues] On Probiotics

Rank Probiotic Impact
species Anaerobutyricum hallii Reduces
species Christensenella minuta Reduces
species Enterococcus faecium Reduces
species Lacticaseibacillus paracasei Reduces
species Lactococcus cremoris Reduces
species Parabacteroides distasonis Reduces

Bacteria Impacted by flavoxate hydrochloride,(prescription) [Can cause cognitive issues]

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

πŸ““ Direct Citations πŸ‘ͺπŸ‘Ά Indirect Citations Taxonomy Rank Effect
0 1 Ruminococcus genus Decreases
0 1 Coprococcus genus Decreases
0 1 Bacteroides genus Decreases
0 1 Lacticaseibacillus genus Decreases
0 1 Parabacteroides genus Decreases
0 1 Roseburia genus Decreases
0 1 Lachnospira genus Decreases
1 0 Ruminococcus bromii species Decreases
1 0 Coprococcus comes species Decreases
1 0 Bacteroides fragilis species Decreases
1 0 Lacticaseibacillus paracasei species Decreases
0 1 Lactococcus cremoris species Decreases
0 1 Streptococcus suis species Decreases
1 0 Bacteroides xylanisolvens species Decreases
1 0 Parabacteroides distasonis species Decreases
0 1 Anaerobutyricum hallii species Decreases
0 1 Adlercreutzia equolifaciens species Decreases
1 0 Roseburia intestinalis species Decreases
0 1 Blautia sp. SC05B48 species Decreases
0 1 Adlercreutzia hattorii species Decreases
0 1 Komagataeibacter oboediens species Decreases
0 1 Fannyhessea vaginae species Decreases
0 1 Bacillus paralicheniformis species Decreases
0 1 Acutalibacter muris species Decreases
0 1 Eubacterium sp. c-25 species Decreases
0 1 Parvimonas micra species Decreases
0 1 Coprococcus catus species Decreases
0 1 Lachnoanaerobaculum gingivalis species Decreases
0 1 Dorea longicatena species Decreases
0 1 Faecalibaculum rodentium species Decreases
0 1 Blautia liquoris species Decreases
0 1 Enterococcus faecium species Decreases
0 1 Christensenella minuta species Decreases
0 1 Mogibacterium diversum species Decreases
0 1 Treponema denticola species Decreases
0 1 Actinomyces oris species Decreases
0 1 Faecalitalea cylindroides species Decreases
0 1 Blautia obeum species Decreases
0 1 Qiania dongpingensis species Decreases
0 1 Dorea formicigenerans species Decreases
0 1 Novisyntrophococcus fermenticellae species Decreases
0 1 Maliibacterium massiliense species Decreases
0 1 Wansuia hejianensis species Decreases
1 0 Lachnospira eligens species Decreases
0 1 Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases
0 1 Lacticaseibacillus paracasei subsp. tolerans subspecies Decreases

Impact of flavoxate hydrochloride,(prescription) [Can cause cognitive issues] on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
ADHD 0.5 0.4 0.25
Age-Related Macular Degeneration and Glaucoma 0.1 0.1 0
Allergic Rhinitis (Hay Fever) 0.2 0.2
Allergies 1.1 1.1 0
Allergy to milk products 0.7 0.3 1.33
Alopecia (Hair Loss) 0.1 0.1
Alzheimer's disease 1 1.4 -0.4
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.4 0.5
Ankylosing spondylitis 0.3 0.5 -0.67
Anorexia Nervosa 0.4 0.9 -1.25
Antiphospholipid syndrome (APS) 0.1 0.1
Asthma 0.6 0.2 2
Atherosclerosis 1 0.2 4
Atrial fibrillation 1.2 0.2 5
Autism 1.3 1.4 -0.08
Autoimmune Disease 0.1 -0.1
benign prostatic hyperplasia 0.1 -0.1
Bipolar Disorder 0.5 0.7 -0.4
Brain Trauma 0.5 -0.5
Cancer (General) 0.3 -0.3
Carcinoma 0.5 0.5 0
Celiac Disease 0.6 0.6 0
Cerebral Palsy 0.1 0.5 -4
Chronic Fatigue Syndrome 1.2 1.9 -0.58
Chronic Kidney Disease 0.3 0.3 0
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.2 0.3 -0.5
Chronic Urticaria (Hives) 0.3 -0.3
Coagulation / Micro clot triggering bacteria 0.1 0.4 -3
Cognitive Function 0.5 0.1 4
Colorectal Cancer 1.1 0.2 4.5
Constipation 0.5 0.1 4
Coronary artery disease 0.5 0.9 -0.8
COVID-19 0.9 2.4 -1.67
Crohn's Disease 1.4 1.4 0
Cushing's Syndrome (hypercortisolism) 0.1 -0.1
cystic fibrosis 0.2 -0.2
deep vein thrombosis 0.6 0.5 0.2
Denture Wearers Oral Shifts 0.1 0.1
Depression 1.7 1.8 -0.06
Eczema 0.3 -0.3
Endometriosis 0.4 0.7 -0.75
Epilepsy 0.6 0.2 2
erectile dysfunction 0.1 0.1
Fibromyalgia 0.1 0.6 -5
Functional constipation / chronic idiopathic constipation 1.3 1.2 0.08
gallstone disease (gsd) 0.9 0.1 8
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.3 0.3 0
Generalized anxiety disorder 0.4 0.4 0
Gout 0.6 0.2 2
Graves' disease 0.5 0.5 0
Gulf War Syndrome 0.2 0.3 -0.5
Halitosis 0.1 0.1
Hashimoto's thyroiditis 1 0.2 4
Heart Failure 0.9 0.5 0.8
hemorrhagic stroke 0.1 0.1
Hidradenitis Suppurativa 0.2 0.2
High Histamine/low DAO 0.1 0.4 -3
hypercholesterolemia (High Cholesterol) 0.1 -0.1
hyperglycemia 0.2 -0.2
hypertension (High Blood Pressure 0.6 1.2 -1
Hypothyroidism 0.2 -0.2
Hypoxia 0.2 0.2
IgA nephropathy (IgAN) 0.5 0.1 4
Inflammatory Bowel Disease 0.5 2.4 -3.8
Insomnia 0.5 0.6 -0.2
Intelligence 0.4 0.4
Intracranial aneurysms 0.5 0.2 1.5
Irritable Bowel Syndrome 0.9 0.9 0
ischemic stroke 0.5 0.2 1.5
Liver Cirrhosis 1.2 0.8 0.5
Long COVID 0.8 1.8 -1.25
Low bone mineral density 0.3 -0.3
Lung Cancer 0.5 -0.5
Mast Cell Issues / mastitis 0.6 -0.6
ME/CFS with IBS 1.2 -1.2
ME/CFS without IBS 0.1 0.5 -4
Menopause 0.1 -0.1
Metabolic Syndrome 1.2 1.4 -0.17
Mood Disorders 1.8 1.5 0.2
Multiple Sclerosis 0.4 1.5 -2.75
Multiple system atrophy (MSA) 0.4 -0.4
myasthenia gravis 0.1 -0.1
neuropathic pain 0.3 -0.3
Neuropathy (all types) 0.1 -0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.7 1 -0.43
NonCeliac Gluten Sensitivity 0.1 0.1 0
Obesity 1.1 1.5 -0.36
obsessive-compulsive disorder 1.4 0.4 2.5
Osteoarthritis 0.3 0.5 -0.67
Osteoporosis 0.5 0.1 4
Parkinson's Disease 1.9 1.3 0.46
Polycystic ovary syndrome 2 1.1 0.82
Postural orthostatic tachycardia syndrome 0.2 -0.2
Premenstrual dysphoric disorder 0.1 -0.1
Primary sclerosing cholangitis 0.3 1 -2.33
Psoriasis 0.8 0.6 0.33
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 1.7 0.8 1.13
Rosacea 0.4 0.1 3
Schizophrenia 1.1 0.9 0.22
scoliosis 0.2 0.4 -1
sensorineural hearing loss 0.3 0.3
Sjögren syndrome 0.1 0.2 -1
Sleep Apnea 0.6 0.4 0.5
Slow gastric motility / Gastroparesis 0.5 0.5
Small Intestinal Bacterial Overgrowth (SIBO) 0.5 0.5
Stress / posttraumatic stress disorder 0.3 0.5 -0.67
Systemic Lupus Erythematosus 0.8 0.5 0.6
Tic Disorder 0.4 0.4
Tourette syndrome 0.1 -0.1
Type 1 Diabetes 1.2 0.7 0.71
Type 2 Diabetes 1.2 1.3 -0.08
Ulcerative colitis 0.8 1.3 -0.63
Unhealthy Ageing 0.7 0.4 0.75
Vitiligo 0.9 0.5 0.8

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]